Session Information
Date: Wednesday, June 22, 2016
Session Title: Parkinson's disease: Neuroimaging and neurophysiology
Session Time: 12:00pm-1:30pm
Location: Exhibit Hall located in Hall B, Level 2
Objective: The aims of this study were to quantify striatal uptake of 18F-DOPA and 11C-PE2I in the same group of PD patients, to assess the relationship between tracer uptake and clinical severity, and to compare 18F-DOPA with 11C-PE2I in order to establish which tracer is more sensitive in assessing nigro-striatal dysfunction in PD.
Background: Positron emission tomography (PET) with 18F-DOPA has long been regarded as the ‘gold standard’ for assessing the progression in vivo in Parkinson’s disease and for monitoring the efficacy of neuroprotective treatments in clinical trials. Previous studies have reported that 18F-DOPA PET may overestimate striatal dopaminergic nerve terminal density in early Parkinson’s disease (PD) patients. Dopamine transporter radioligands with single photon emission computed tomography have been used to support a diagnosis of PD in clinic. However, DAT quantification using PET technique can provide higher resolution and specificity than that which can be achieved using current SPECT tracers, and this includes the new 11C-PE2I PET.
Methods: The striatal uptakes of 18F-DOPA and 11C-PE2I were compared using PET in 31 PD patients (age mean±SD: 55.46 ± 7.09 years; disease duration mean±SD: 5.7 ± 2.2 years) recruited into the Transeuro study. The correlation of uptakes with UPDRS-III total and sub-scores was also investigated.
Results: There were significant negative correlations between 11C-PE2I uptake bilaterally in the caudate and putamen and total UPDRS-III score (r = 0.51, p = 0.003 and r = -0.51, p =0.004 respectively), and these correlations were more robust than with 18F-DOPA.
Conclusions: 11C-PE2I PET is more closely correlated with clinical phenotype than 18F-DOPA PET in early PD patients and thus is potentially more useful in evaluating disease progression and the efficacy of neuroprotective treatments in PD.
To cite this abstract in AMA style:
W. Li, N.P. Lao-Kaim, A.A. Roussakis, A. Martin-Bastida, C. Loane, N. Valle-Guzman, Z. Kefalopoulou, M. Politis, T. Foltynie, R.A. Barker, P. Piccini. Comparison of DAT and DOPA PET tracer for assessing severity and progression in patients with Parkinson’s disease [abstract]. Mov Disord. 2016; 31 (suppl 2). https://www.mdsabstracts.org/abstract/comparison-of-dat-and-dopa-pet-tracer-for-assessing-severity-and-progression-in-patients-with-parkinsons-disease/. Accessed June 15, 2025.« Back to 2016 International Congress
MDS Abstracts - https://www.mdsabstracts.org/abstract/comparison-of-dat-and-dopa-pet-tracer-for-assessing-severity-and-progression-in-patients-with-parkinsons-disease/